Literature DB >> 27501226

Hypoxia-preconditioned allogeneic mesenchymal stem cells can be used for myocardial repair in non-human primates.

Kuan-Cheng Chang1, Shih-Chieh Hung2.   

Abstract

Entities:  

Year:  2016        PMID: 27501226      PMCID: PMC4958853          DOI: 10.21037/jtd.2016.05.46

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease.

Authors:  Kuei-Chuan Lee; Han-Chieh Lin; Yi-Hsiang Huang; Shih-Chieh Hung
Journal:  J Hepatol       Date:  2015-08-11       Impact factor: 25.083

2.  Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials.

Authors:  Dongming Hou; Eyas Al-Shaykh Youssef; Todd J Brinton; Ping Zhang; Pamela Rogers; Erik T Price; Alan C Yeung; Brian H Johnstone; Paul G Yock; Keith L March
Journal:  Circulation       Date:  2005-08-30       Impact factor: 29.690

3.  Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells.

Authors:  Chih-Chien Tsai; Pei-Fen Su; Yi-Feng Huang; Tu-Lai Yew; Shih-Chieh Hung
Journal:  Mol Cell       Date:  2012-07-12       Impact factor: 17.970

4.  Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST.

Authors:  Chih-Chien Tsai; Yann-Jang Chen; Tu-Lai Yew; Ling-Lan Chen; Jir-You Wang; Chao-Hua Chiu; Shih-Chieh Hung
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

5.  Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Nikos Werner; Jürgen Haase; Jörg Neuzner; Alfried Germing; Bernd Mark; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Eur Heart J       Date:  2006-11-10       Impact factor: 29.983

6.  Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice.

Authors:  Ning Wei; Shan Ping Yu; Xiaohuan Gu; Tammi M Taylor; Denise Song; Xin-Feng Liu; Ling Wei
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

7.  Mesenchymal stem cells from a hypoxic culture improve and engraft Achilles tendon repair.

Authors:  Tung-Fu Huang; Tu-Lai Yew; En-Rung Chiang; Hsiao-Li Ma; Chih-Yuan Hsu; Shan-Hui Hsu; Yuan-Tong Hsu; Shih-Chieh Hung
Journal:  Am J Sports Med       Date:  2013-03-28       Impact factor: 6.202

8.  Hypoxia-preconditioned mesenchymal stromal cells improve cardiac function in a swine model of chronic myocardial ischaemia.

Authors:  Jeremie Jaussaud; Matthieu Biais; Joachim Calderon; Jean Chevaleyre; Pascale Duchez; Zoran Ivanovic; Thierry Couffinhal; Laurent Barandon
Journal:  Eur J Cardiothorac Surg       Date:  2012-10-25       Impact factor: 4.191

Review 9.  The advancing field of cell-based therapy: insights and lessons from clinical trials.

Authors:  Kartik S Telukuntla; Viky Y Suncion; Ivonne H Schulman; Joshua M Hare
Journal:  J Am Heart Assoc       Date:  2013-10-10       Impact factor: 5.501

Review 10.  Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy.

Authors:  Nazmul Haque; Mohammad Tariqur Rahman; Noor Hayaty Abu Kasim; Aied Mohammed Alabsi
Journal:  ScientificWorldJournal       Date:  2013-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.